Hiring in Pharmaceuticals

• Clinical development

  Clinical scientists · Study directors · Medical monitors · Clinical operations leads

• Regulatory affairs

  Regulatory scientists · Regulatory affairs managers · Heads of regulatory

• Medical affairs

  Medical Science Liaisons (MSLs) · Medical directors · Publications leads

• R&D

  Medicinal chemists · Pharmacologists · Bioinformaticians

• Commercial

  Brand leads · Market-access professionals · KAMs

• Therapeutic-area depth

  Oncology, immunology, CNS, rare disease and cardiometabolic each demand distinct evidence. TA captured at intake.

• Phase specialisation

  Discovery, Phase I/II/III and post-market surveillance reward different signal — never merged in scoring.

• Regulatory pathway

  FDA, EMA, MHRA, PMDA — captured with submission history where evidenced.

• GxP discipline

  GCP, GLP, GMP, GVP ownership surfaced from the CV.

Every candidate is scored against the role's rubric, and every score points back to a specific line in the CV. For pharmaceuticals, these are the signals that carry weight:

• TA and phase rubric
• Submission history captured
• GxP evidence from CV

• RAC
• PharmD / PhD / MD
• GCP training

• GxP compliance
• Sponsor accountability for regulated tasks

1. A ranked set of candidates, each with a score and the evidence behind it.
2. Eligibility checks resolved before the candidate reaches you — right to work, credentials, location model.
3. Salary expectation against your band, stated plainly, before you invest interview time.
4. One decision per candidate: advance, hold or decline, reversible for a short window.

Candidates stay invisible to you until we've reviewed them for your specific role, and contact details are released as a separate step.